Cargando…

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Given the multi-faceted pathogenesis of atherosclerosis in type 2 diabetes mellitus (T2DM), it is likely that interventions to mitigate this risk must address cardiovascular (CV) risk factors beyond glucose itself. Sodium glucose cotransporter-2 (SGLT-2) inhibitors are newer antihyperglycaemic agent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inzucchi, Silvio E, Zinman, Bernard, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Hantel, Stefan, Espadero, Rosa-Maria, Woerle, Hans-Jürgen, Broedl, Uli C, Johansen, Odd Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Feature Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361459/ https://www.ncbi.nlm.nih.gov/pubmed/25589482 http://dx.doi.org/10.1177/1479164114559852

Ejemplares similares

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Fluorosis: an ongoing challenge for India
por: Del Bello, Lou
Publicado: (2020)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
por: Perkins, Bruce A., et al.
Publicado: (2015)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
por: Ridderstråle, Martin, et al.
Publicado: (2013)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
por: Ruggenenti, Piero, et al.
Publicado: (2021)

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials
por: Salsali, A., et al.
Publicado: (2016)

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
por: Neeland, Ian J, et al.
Publicado: (2016)

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
por: Neeland, Ian J., et al.
Publicado: (2015)

Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
por: Neeland, Ian J., et al.
Publicado: (2018)

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
por: Sattar, Naveed, et al.
Publicado: (2018)

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
por: Cherney, David ZI, et al.
Publicado: (2014)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Association between uric acid levels and cardio‐renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2020)

Forever young? The ethics of ongoing puberty suppression for non-binary adults
por: Notini, Lauren, et al.
Publicado: (2020)

News from the Funding Front: Upcoming Opportunities, Proposals Welcomed
por: Vasaly, Helen L., et al.
Publicado: (2013)

COVID-19 Pandemic, Personality and Geriatric Population: Proposed Pragmatism
por: Dubey, Souvik, et al.
Publicado: (2021)

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
por: Rosenstock, Julio, et al.
Publicado: (2018)

Technologies and therapeutics for ongoing prevention of respiratory infections
por: David, Shannon C
Publicado: (2023)

Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia
por: Ji, Qiuhe, et al.
Publicado: (2021)

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2023)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
por: McGuire, Darren K., et al.
Publicado: (2021)

Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
por: Neeland, Ian J., et al.
Publicado: (2021)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
por: Pellicori, Pierpaolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gg5g1e3gml4imbfiiduk80qmu2